Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC.TMCI · Entity 5943 | Director | March 15, 2023 | March 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TREACE MEDICAL CONCEPTS, INC.
Report date March 15, 2023 · Filed March 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectThomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001 | 1,149,069 |
Reported balance
After 2023-03-15 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-03-15 · Sale · Disposed 50,000 · Balance 1,149,069 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.7500 to $23.4300 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectPamela Timbie and Thomas Timbie as Trustees of the PAMELA F TIMBIE REV TRUST | 361,700 |
Reported balance
Holding disclosure · report date 2023-03-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 361,700 |
| Common StockSEC Table I · non-derivative | Direct | 2,295 |
Reported balance
Holding disclosure · report date 2023-03-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,295 F3: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on May 17, 2023 subject to Reporting Person's providing continued service to Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.7500 to $23.4300 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on May 17, 2023 subject to Reporting Person's providing continued service to Issuer through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2023 Filed Mar 17, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 50,000 | $23.03 | $1,151,665.00 |
DisclosureSEC source: 0001209191-23-019943 · doc4.xml · nonDerivative · entry 1 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001 Disclosed balance after: 1,149,069 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.7500 to $23.4300 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 17:52 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GiftCommon Stock | 8,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-010852 · doc4.xml · nonDerivative · entry 2 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Pamela Timbie and Thomas Timbie as Trustees of the PAMELA F TIMBIE REV TRUST Disclosed balance after: 361,700 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 17:52 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 50,000 | $21.71 | $1,085,350.00 |
DisclosureSEC source: 0001209191-23-010852 · doc4.xml · nonDerivative · entry 1 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001 Disclosed balance after: 1,199,069 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $21.4800 to $22.1380 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 18, 2023 Filed Jan 20, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 50,000 | $25.88 | $1,294,000.00 |
DisclosureSEC source: 0001209191-23-004342 · doc4.xml · nonDerivative · entry 1 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001 Disclosed balance after: 1,249,069 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.5400 to $26.5000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 50,000 | $24.00 | $1,199,935.00 |
DisclosureSEC source: 0001209191-22-061757 · doc4.xml · nonDerivative · entry 1 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001 Disclosed balance after: 1,299,069 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.4900 to $24.2400 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 22, 2022 Filed Nov 22, 2022 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 10,070 | $22.11 | $222,597.35 |
DisclosureSEC source: 0001209191-22-058549 · doc4.xml · nonDerivative · entry 4 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001 Disclosed balance after: 1,349,069 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.020 to $22.640 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 224 | $22.08 | $4,946.82 |
DisclosureSEC source: 0001209191-22-058549 · doc4.xml · nonDerivative · entry 3 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001 Disclosed balance after: 1,359,139 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.010 to $22.180 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 2,101 | $23.46 | $49,278.96 |
DisclosureSEC source: 0001209191-22-058549 · doc4.xml · nonDerivative · entry 2 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001 Disclosed balance after: 1,359,363 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.250 to $23.610 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 37,605 | $22.66 | $852,091.70 |
DisclosureSEC source: 0001209191-22-058549 · doc4.xml · nonDerivative · entry 1 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001 Disclosed balance after: 1,361,464 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.250 to $23.230 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 20:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 50,000 | $20.14 | $1,006,900.00 |
DisclosureSEC source: 0001209191-22-058000 · doc4.xml · nonDerivative · entry 1 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001 Disclosed balance after: 1,399,069 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.760 to $20.370 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2022 Filed Feb 14, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GiftCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009582 · doc5.xml · nonDerivative · entry 1 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Pamela Timbie and Thomas Timbie as Trustees of the PAMELA F TIMBIE REV TRUST Disclosed balance after: 370,000 Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 20:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 50,000 | $19.91 | $995,500.00 |
DisclosureSEC source: 0001209191-22-046491 · doc4.xml · nonDerivative · entry 1 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001 Disclosed balance after: 1,449,069 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.475 to $20.12 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 05, 2022 Filed Aug 5, 2022 18:01 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 4,904 | $19.04 | $93,372.65 |
DisclosureSEC source: 0001209191-22-044621 · doc4.xml · nonDerivative · entry 3 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001 Disclosed balance after: 1,499,069 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.91 to $19.34 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 18:01 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 48,217 | $18.56 | $894,724.30 |
DisclosureSEC source: 0001209191-22-044621 · doc4.xml · nonDerivative · entry 2 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001 Disclosed balance after: 1,503,973 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.50 to $19.03 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 18:01 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 96,879 | $18.85 | $1,825,868.83 |
DisclosureSEC source: 0001209191-22-044621 · doc4.xml · nonDerivative · entry 1 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001 Disclosed balance after: 1,552,190 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.50 to $19.17 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 17, 2022 Filed May 19, 2022 20:38 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantStock Option (Right to Buy) · Derivative | 16,625 | $0.00 Strike: $15.80 | $0.00 |
DisclosureSEC source: 0001567619-22-011344 · doc1.xml · derivative · entry 4 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,625 Underlying: Common Stock · 16,625 shares Expires 2032-05-17 F2 · derivative.exercise_date: The stock option will vest in 12 substantially equal monthly installments, commencing on June 17, 2022, such that the stock option will be fully vested and exercisable on May 17, 2023, subject to Reporting Person's providing continued service to Issuer through each vesting date. Read SEC document |
| May 17, 2022 Filed May 19, 2022 20:38 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 2,295 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-011344 · doc1.xml · nonDerivative · entry 1 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,295 F1 · shares: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on May 17, 2023 subject to Reporting Person's providing continued service to Issuer through the vesting date. Read SEC document |
| May 09, 2022 Filed May 19, 2022 20:38 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GiftCommon Stock | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-011344 · doc1.xml · nonDerivative · entry 2 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Pamela Timbie and Thomas Timbie as Trustees of the PAMELA F TIMBIE REV TRUST Disclosed balance after: 385,000 Read SEC document |
| January 13, 2022 Filed Mar 10, 2022 20:22 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GiftCommon Stock | 95,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-006728 · doc1.xml · nonDerivative · entry 1 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Pamela Timbie and Thomas Timbie as Trustees of the PAMELA F TIMBIE REV TRUST Disclosed balance after: 505,000 Read SEC document |
| December 09, 2021 Filed Feb 11, 2022 16:27 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 600,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-003543 · doc1.xml · nonDerivative · entry 2 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Pamela Timbie and Thomas Timbie as Trustees of the PAMELA F TIMBIE REV TRUST Disclosed balance after: 600,000 Read SEC document |
| December 09, 2021 Filed Feb 11, 2022 16:27 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GiftCommon Stock | 600,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-003543 · doc1.xml · nonDerivative · entry 1 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001 Disclosed balance after: 1,649,069 Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 21:35 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 11,171 | $25.18 | $281,244.45 |
DisclosureSEC source: 0001567619-21-018626 · doc1.xml · nonDerivative · entry 3 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001 Disclosed balance after: 2,249,069 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25 to $25.54 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 07, 2021 Filed Oct 22, 2021 21:35 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GiftCommon Stock | 280,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-018626 · doc1.xml · nonDerivative · entry 2 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001 Disclosed balance after: 2,260,240 F3 · shares: Gifted to irrevocable trust with a third party trustee for the benefit of a different natural person. Read SEC document |
| September 07, 2021 Filed Oct 22, 2021 21:35 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GiftCommon Stock | 280,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-018626 · doc1.xml · nonDerivative · entry 1 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001 Disclosed balance after: 2,540,240 F2 · shares: Gifted to irrevocable trust with a third party trustee for the benefit of a natural person. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:17 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | ConversionSeries A Preferred Stock · Derivative | 299,509 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-017480 · doc4.xml · derivative · entry 3 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001 Disclosed balance after: 0 Underlying: Common Stock · 299,509 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:17 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | OtherSeries A Preferred Stock · Derivative | 6,931 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-017480 · doc4.xml · derivative · entry 2 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001 Disclosed balance after: 299,509 Underlying: Common Stock · 6,931 shares Expires not disclosed F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date F2 · derivative.exercise_price: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend. F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date F2 · derivative.exercise_date: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend. F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date F2 · derivative.expiration_date: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:17 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | ConversionCommon Stock | 299,509 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-017480 · doc4.xml · nonDerivative · entry 1 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001 Disclosed balance after: 2,820,240 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date Read SEC document |
| April 22, 2021 Filed Apr 26, 2021 21:06 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantStock Option Right to Buy · Derivative | 21,240 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-21-017036 · doc4.xml · derivative · entry 1 TIMBIE THOMAS E · CIK 0001188309 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,240 Underlying: Common Stock · 21,240 shares Expires 2031-04-22 F1 · derivative.exercise_date: The stock option will vest in 12 substantially equal installments, commencing on May 22, 2021, such that the stock option will be fully vested and exercisable on April 22, 2022, subject to Reporting Person's providing continued service to Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.